Inventaire - je vrienden en communities zijn je beste bibliotheek

Cell culture-derived influenza vaccines in the severe 2017-2018 epidemic season: a step towards improved influenza vaccine effectiveness

auteur

David E Wentworth

Jacqueline M. Katz

Ruben O Donis

Takato Odagiri

Ian G. Barr

gepubliceerd in: npj Vaccines

publicatiedatum: 2018

taal: Engels

belangrijk thema: griepprik, epidemie

Cites articles 33

Date

Titel

Auteurs

2018-06-08

Update: Influenza Activity in the United States During the 2017-18 Season and Composition of the 2018-19 Influenza Vaccine.

Alissa O'Halloran, Lynnette Brammer, Lenee Blanton, Desiree Mustaquim, Matthew Biggerstaff, Larisa Gubareva, Krista Kniss, David E Wentworth, Daniel Jernigan, Jacqueline M. Katz, Alicia M Fry, Erin Burns, Vivien G Dugan, Charisse N Cummings
2018-03-01

Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies.

Amparo Larrauri, Ramona Trebbien, Jim McMenamin, Inmaculada Casas, Hanne-Dorthe Emborg
2018-02-16

Update: Influenza Activity - United States, October 1, 2017-February 3, 2018.

Alissa O'Halloran, Lynnette Brammer, Lenee Blanton, Desiree Mustaquim, Larisa Gubareva, Krista Kniss, David E Wentworth, Daniel Jernigan, Jacqueline M. Katz, Alicia M Fry, Erin Burns, Vivien G Dugan, Sonja J Olsen, John Barnes, Charisse N Cummings, Brendan Flannery
2018-02-16

Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018.

Edward A Belongia, Arnold S Monto, Richard Zimmerman, Mary Patricia Nowalk, Alicia M Fry, John Barnes, Lisa A Jackson, Brendan Flannery, Manjusha Gaglani, Huong Q McLean, Michael L Jackson, Emily T Martin, LaShondra Berman, Angie Foust, Kempapura Murthy, Margaret Chung
2018-02-01

Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018.

Catharine Chambers, Yan Li, Nathalie Bastien, Mel Krajden, Hugues Charest, Gaston De Serres, Jonathan B Gubbay, Danuta M. Skowronski, James A Dickinson, Anne-Luise Winter, Steven J Drews, Agatha N Jassem, Tracy Chan
2018-03-23

Recommended composition of influenza virus vaccines for use in the 2018–2019 northern hemisphere influenza season
2017-10-01

Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017.

Sheena Sullivan, Monique Chilver, Yi-Mo Deng, N P Stocks, N Komadina, Kylie S Carville, Kristina A. Grant, James E Fielding
2017-06-01

Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older
2017-04-01

Excess all-cause and influenza-attributable mortality in Europe, December 2016 to February 2017

Kåre Mølbak, Susana Silva, Cornelia Adlhoch, Pasi M Penttinen, Theodore Lytras, Kaire Innos, Amparo Larrauri, Neville Calleja, Matteo Scortichini, Liselotte van Asten, Tyra Grove Krause, Lasse S Vestergaard
2017-03-02

Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries in Preventing Postinfluenza Deaths During 2012-2013 and 2013-2014.

Alicia M Fry
2017-01-25

Improving the selection and development of influenza vaccine viruses - Report of a WHO informal consultation on improving influenza vaccine virus selection, Hong Kong SAR, China, 18-20 November 2015

Daniel Jernigan, Jacqueline M. Katz, Ruben O Donis, Richard Webby, Takato Odagiri, Nancy Cox, Ian G. Barr, Anthony L Waddell, Alan W. Hampson, John W McCauley, Wenqing Zhang, John S Tam, Siddhivinayak Hirve, Thedi Ziegler, Fernando Motta
2016-07-25

Development of an Influenza A Master Virus for Generating High-Growth Reassortants for A/Anhui/1/2013(H7N9) Vaccine Production in Qualified MDCK Cells

Takato Odagiri
2016-05-06

Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015.

Edward A Belongia, Arnold S Monto, Richard Zimmerman, Mary Patricia Nowalk, Jacqueline M. Katz, Alicia M Fry, John Barnes, Suzanne E Ohmit, Larisa Gubareva, Vasiliy P Mishin, Lisa A Jackson, Brendan Flannery, Manjusha Gaglani, Huong Q McLean, Michael L Jackson, Swathi N Thaker, Angie Foust, Margaret Chung, Rebecca J Garten
2016-04-06

Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies

Edward A Belongia, Jennifer P King, Michael T. Osterholm, Huong Q McLean, Maria E Sundaram, Nicholas S. Kelley
2016-03-09

Influenza Vaccine Manufacturing: Effect of Inactivation, Splitting and Site of Manufacturing. Comparison of Influenza Vaccine Production Processes

Adrian Onu, Gideon Kersten
2015-02-09

Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis

Richard Forshee, David K. Shay
2014-10-28

Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review

Sheena Sullivan, Benjamin J. Cowling
2014-06-24

Performance characteristics of qualified cell lines for isolation and propagation of influenza viruses for vaccine manufacturing

Ruben O Donis, Alexander I Klimov, Thedi Ziegler
2014-03-25

Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses

James A Dickinson, Salaheddin M. Mahmud, Naveed Zafar Janjua, Yan Li, Nathalie Bastien, Mel Krajden, Hugues Charest, Gaston De Serres, Jonathan B Gubbay, Danuta M. Skowronski, Alireza Eshaghi, Suzana Sabaiduc, Martin Petric, Anne-Luise Winter, Kevin Fonseca, Paul Van Caeseele, Trijntje L Kwindt
2013-12-01

Surface modifications of influenza proteins upon virus inactivation by β-propiolactone

Yi-Min She
2011-11-24

Isolation of influenza viruses in MDCK 33016PF cells and clearance of contaminating respiratory viruses
2011-10-01

Oil-in-water emulsion adjuvant with influenza vaccine in young children

Heinz-Josef Schmitt
2010

Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza

Emanuele Montomoli
2010-11-01

Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.

Sharon E Frey
2010-09-01

Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine

Ruth Frances Jarrett
2010-05-01

The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response

Hong Jin
2010-02-10

Effect of inactivation method on the cross-protective immunity induced by whole 'killed' influenza A viruses and commercial vaccine preparations
2009-10-01

Public health. Rethinking influenza

Ab Osterhaus, Rino Rappuoli, Gary Nabel, Klaus Stöhr
2009-02-27

Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK.

Othmar G Engelhardt, Otfried Kistner, Richard M Schwartz
2004-10-01

Antigenic alteration of influenza B virus associated with loss of a glycosylation site due to host-cell adaptation

Takato Odagiri, Takashi Suzuki
1989-08-01

Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs

Robert Webster
1987-12-01

Egg-grown and tissue-culture-grown variants of influenza A (H3N2) virus with special attention to their use as antigens in seroepidemiology

Artike - wd:Q57480742

Welcome to Inventaire

de bibliotheek van je vrienden en communities

meer leren